Evidence map›Paper›PMID 36230656›Full record

ArticleCancers2022

Oncogenic Role of ADAM32 in Hepatoblastoma: A Potential Molecular Target for Therapy.

Takahiro Fukazawa, Keiji Tanimoto, Emi Yamaoka, Masato Kojima, Masami Kanawa, Nobuyuki Hirohashi, Eiso Hiyama

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. The Effects ofAnimals : an open access journal from MDPI · 2024
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Takahiro FukazawaNatural Science Center for Basic Research and Development, Hiroshima University, Hiroshima 734-8553, Japan.
Keiji TanimotoDepartment of Radiation Disaster Medicine, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima 734-8553, Japan.ORCID 0000-0003-4912-4197
Emi YamaokaNatural Science Center for Basic Research and Development, Hiroshima University, Hiroshima 734-8553, Japan.
Masato KojimaDepartment of Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.
Masami KanawaNatural Science Center for Basic Research and Development, Hiroshima University, Hiroshima 734-8553, Japan.ORCID 0000-0003-2289-9320
Nobuyuki HirohashiDepartment of Radiation Disaster Medicine, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima 734-8553, Japan.ORCID 0000-0001-6237-214X
Eiso HiyamaNatural Science Center for Basic Research and Development, Hiroshima University, Hiroshima 734-8553, Japan.ORCID 0000-0001-9179-5037
Hiroshima University · JP

Funding

Innovative Cancer Control from the Japan Agency Medical Research 19ck0106332h0003Japan Society for the Promotion of Science JP17K16265Japan Society for the Promotion of Science JP20K17554
6 · The paper itself

Abstract

Outcomes of pediatric hepatoblastoma (HBL) have improved, but refractory cases still occur. More effective and safer drugs are needed that are based on molecular mechanisms. A disintegrin and metalloproteases (ADAMs) are expressed with high frequency in various human carcinomas and play an important role in cancer progression. In this study, we analyzed expression of

Indexed as

ADAM32apoptosiscell mobilityhepatoblastomastemness

Identifiers

PMID36230656
PMCPMC9562177
OpenAlexW4297464478

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.